Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis / 中国药科大学学报
Journal of China Pharmaceutical University
; (6): 36-44, 2024.
Article
em Zh
| WPRIM
| ID: wpr-1025630
Biblioteca responsável:
WPRO
ABSTRACT
C-C motif chemokine ligand 2(CCL2)and its receptor CCR2 are closely related to tumorigenesis and tumor progression.The CCL2/CCR2 signaling axis promotes tumor progression through multiple mechanisms:CCL2 binds to CCR2 on the surface of tumor cells,and thus promotes tumor growth/survival and metastasis;more importantly,CCL2 recruits a variety of immunosuppressive cells to aggregate in the tumor microenvironment,and inhibits the function and activity of immune cells,promoting tumor progression.The article reviews the CCL2/CCR2 signaling axis and its role in tumors and tumor microenvironment,with particular focus on the advances in clinical research on drugs targeting CCL2/CCR2 signaling axis,in order to gain an in-depth and overall understanding of the mechanism of action of CCL2/CCR2 axis in tumor progression and develop more effective anti-tumor immunotherapeutic agents.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of China Pharmaceutical University
Ano de publicação:
2024
Tipo de documento:
Article